

FEB 14 2006

Dkt. No.:19240-477.US2

Application Serial No.: 10/799,941

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Serial No.: 10/799,941 **Confirmation No.:** 8041

Applicant: WELCH, M. et al.

Filed: March 11, 2004

Group Art Unit: 1654

Examiner: HARLE, Jennifer I.

Title: Novel Multipeptide Regimen for the Treatment of Autistic Spectrum, Behavioral, Emotional and Visceral Inflammation/Autoimmune Disorders

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO NOVEMBER 15, 2005 RESTRICTION REQUIREMENT

Dear Sir:

This paper is being filed in response to the Office Communication mailed on November 15, 2005. A reply was due on December 15, 2005. Applicants request a two-month extension of time, which makes the reply due on February 15, 2006. Therefore, this paper is being filed timely. The Commissioner is hereby authorized to charge any fees required for the submission of this paper, any deficiency in the fees filed or credit any overpaid fees to Deposit Account No. 08-0219.

In the Office Communication of November 15, 2005, the Examiner required Applicants to elect a group of claims for examination. In response, Applicants elect Group I.


The Examiner required election of a species of a specific disorder among the diseases. Applicants elect Irritable Bowel Disease (IBD).

Dkt. No.:19240-477.US2
Application Serial No.: 10/799,941

The Examiner required the election of a species of a specific protease inhibitor.

Applicants elect the species of INVIRASE®.

Respectfully submitted,



Jane M. Love, Ph.D.
Reg. No. 42,812

Date: 2/14/06

Wilmer Cutler Pickering Hale and Dorr LLP
399 Park Avenue
New York, New York 1002
Tel: (212) 937-7233
Fax: (212) 230-8888